Insights & Resources – COD Research – Designing Therapies For Future

Medical Affairs

CT Quality Assurance

Clinical Services

Biometrics

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Strategic Planning for Patient Recruitment

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

EMA
FDA
MHRA

Human medicines European public assessment report (EPAR): Hyftor, sirolimus, Date of authorisation: 15/05/2023, Revision: 3, Status: Authorised
Source: EMA Published on 2025-07-04
Human medicines European public assessment report (EPAR): Strimvelis, autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, Date of authorisation: 26/05/2016, Revision: 12, Status: Authorised
Source: EMA Published on 2025-07-04
Human medicines European public assessment report (EPAR): ProQuad, measles, mumps, rubella and varicella vaccine (live), Date of authorisation: 05/04/2006, Revision: 34, Status: Authorised
Source: EMA Published on 2025-07-04
Human medicines European public assessment report (EPAR): Jivi, damoctocog alfa pegol, Date of authorisation: 22/11/2018, Revision: 6, Status: Authorised
Source: EMA Published on 2025-07-04
Human medicines European public assessment report (EPAR): Palforzia, defatted powder of Arachis hypogaea L., semen (peanuts), Date of authorisation: 17/12/2020, Revision: 10, Status: Authorised
Source: EMA Published on 2025-07-04
Human medicines European public assessment report (EPAR): Rilonacept FGK Representative Service GmbH , rilonacept, Status: Application withdrawn
Source: EMA Published on 2025-07-04

Read More